Keep up to date with our latest partnering deals and highlights
Below is a selection of news releases describing recent deals completed by AstraZeneca and our biologics arm, MedImmune.
- Tuesday, 15 October 2013
- AstraZeneca oncology portfolio strengthened as MedImmune acquisition of Spirogen boosts antibody-drug conjugate capability AstraZeneca today announced that MedImmune, its global biologics research and development arm, has acquired Spirogen, a privately-held biotech company focused on antibody-drug conjugate technology for use in oncology.
- Friday, 11 October 2013
- AstraZeneca enters co-promotion agreement with Janssen in Japan for innovative prostate cancer treatment AstraZeneca today announced that it has entered into an agreement with Janssen Pharmaceuticals K. K. in Japan to co-promote abiraterone acetate, an innovative oral therapy for the treatment of patients with prostate cancer.
- Wednesday, 11 September 2013
- AstraZeneca and Merck enter licence agreement for investigational oral WEE1 kinase inhibitor therapy for cancer AstraZeneca and Merck & Co Inc , known outside the United States and Canada as MSD, today announced a worldwide licensing agreement.